Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis
Summary
BOSTON, June 22, 2022 /PRNewswire/ -- Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced the closing of a $27 Million Series B financing round. The capability to discern complex plaque biology at the cellular and molecular level is powering new applications that can derive fractional flow reserve (FFRct), risk of heart attack/stroke, and expression prediction to inform therapeutic selection. ""Elucids basis in histopathology is highly differentiated from competitive methods and is paramount to understanding the key drivers of atherosclerosis which cause ischemia and heart attacks," said John Fichthorn of MedTex Ventures. "About ElucidElucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts ("Virtual Transcriptomics").
Funding
Review available funding amount, funding date, investors, and linked company information related to Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis in the interactive ISVWorld profile.